Back to Multiple Sclerosis
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00493298

NCT00493298
Completed Not Applicable 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You must have been diagnosed with Relapsing Remitting Multiple Sclerosis (a form of MS where symptoms come and go in episodes)
  • Your doctor must have already decided that Tysabri (a specific MS medication) is the right treatment for you before you sign up for the trial
  • You must be new to Tysabri, meaning you have had no more than 3 Tysabri infusions before joining
  • You must have had at least one MS relapse (a flare-up of symptoms) in the past year, and meet the local approved guidelines for receiving Tysabri

Who may not be able to join:

  • You have a history of a serious brain infection called Progressive Multifocal Leukoencephalopathy (PML), other serious opportunistic infections, or you are at higher risk of getting these types of infections (confirm with trial site)
  • You have previously tested positive for antibodies against Tysabri (meaning your body has shown a reaction against the drug)
  • You are currently taking other medications that affect or suppress your immune system alongside Tysabri
  • Your immune system is already weakened at the time of joining the trial
  • You currently have a known active cancer
  • You are pregnant, breastfeeding, or planning to become pregnant during the trial — women who are able to become pregnant must use a reliable form of birth control unless they have had a surgical procedure that prevents pregnancy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Biogen
Registry
clinicaltrials_gov
Start date
29 June 2007
Est. completion
1 November 2023

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇿 Czechia 🇫🇮 Finland 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇮🇹 Italy 🇲🇽 Mexico 🇳🇱 Netherlands 🇳🇴 Norway 🇵🇹 Portugal 🇸🇰 Slovakia 🇪🇸 Spain 🇬🇧 United Kingdom

14 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of Participants with Serious Adverse Events (SAE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov